Exelixis' Cancer-Drug Deadline Just Slipped to 2027—but the Stock Was Already Priced for It

On September 10, the Food and Drug Administration told Exelixis it needed more time on the company's experimental cancer drug zanzalintinib, extending its review by three months and moving the decision from December 3 of this year to March 3, 2027. The stock slipped about 3.5% before the bell the next day, then settled. A delay to a filing deadline usually reads as noise. It is the calendar, not the clinical verdict, that is doing the interesting work here — because the calendar is how long the market has already been paying front of the price.

The reason this deadline matters more than most is that nearly every future dollar of growth Exelixis is priced for sits on one drug that is not yet approved. Zanzalintinib is the company's hand-picked successor to Cabometyx, the kidney- and liver-cancer drug that today is the entire revenue engine. Exelixis' ambition, stated in investor materials, is to become a top-five solid-tumor company by U.S. sales, and zanzalintinib is the vehicle.

The drug the growth story leans on

Cabometyx is a mature, extremely profitable franchise rather than a growth story on its own. In the second quarter of 2026, the company booked $628.7 million in total revenue, of which $573 million came from the cabozantinib franchise. The broader financial picture is that of a healthy, cash-generative company: trailing free cash flow of roughly $1.16 billion, essentially no net debt, an operating margin near 40%. Exelixis does not need this drug to survive. It needs it to grow — which is exactly why the stock's premium exists.

That is the setup the extension intrudes on. The most recent reading of the pivotal data, released in June from the phase 3 STELLAR-303 trial, was genuinely mixed. The trial tested zanzalintinib plus Roche's immunotherapy Tecentriq against the older drug regorafenib in patients with previously treated metastatic colorectal cancer. It had two primary survival endpoints: overall survival across the whole study population, and overall survival in the subgroup of patients without liver metastases. Exelixis cleared the first — a statistically significant improvement of about 20%, the kind of result that wins an approval — but missed the second, where the improvement was numerical rather than significant. The trial's own success criteria required only that one of the two endpoints hit, which is likely why analysts from firms including Leerink and William Blair argued the FDA would still be comfortable.

What deserves scrutiny is that this approval path does not arrive at the FDA clean. The trial's design changed twice during its run — the liver-metastases-subset endpoint was at one point made the sole primary test before overall survival was restored to a co-primary role — and the subgroup that once looked strongest is now the one that failed to confirm. Analysts have flagged that the eventual label could simply exclude the non-liver-metastases population, narrowing the approved business rather than growing it.

The benign explanation for this week's slip is credible and should be given its weight. The FDA informed Exelixis, via a "major amendment" to the application, that it wanted updated safety and efficacy data; the company supplied it. Major amendments routinely buy the agency an extra three months, and an information request is not the same as a rejection, a delay for an advisory committee, or a safety signal. The agencies did not identify a specific clinical concern. This is, on the evidence available, a scheduling event.

What the three months actually cost

But an investor does not have to call it a rejection to price its effect. The useful frame is to compare the change to the market's expectations, not to the FDA's process.

The stock trades near its 52-week high of about $59.72 and is up more than 40% over the past year, after rising 36% in just the last 120 days. That run was built on a story: zanzalintinib gets approved by year-end 2026 and becomes the second engine under a company that still prints more than a billion in annual free cash flow from Cabometyx. This week's extension pushes the earliest possible approval — and therefore the earliest material commercial contribution — into 2027, on a drug whose pivotal data is already narrower than the original pitch.

That is the shareholder invoice, and it is a valuation bill rather than a solvency one. Because Exelixis carries no net debt and its current drug funds the whole machine, nothing about the delay endangers the balance sheet. The expense is time and certainty: the investor holding the stock today is paying a full growth premium for an inflection that just moved several months further out, for a molecule that cleared its broadest test but stumbled on the precise subgroup that might have defined its most attractive label.

The market's own mild reaction — a roughly 3.5% premarket dip, a modest intraday move — is telling. It says most holders read the extension as exactly what the company says it is: a delay, not a denial. That is probably right. It is also the point. When a stock's entire growth premium rests on a single still-unapproved drug, even a benign three-month slip is a reminder of how much of the price is a bet on a calendar rather than a business the company already owns.

What to watch next

The next settlement in this story is the new decision date, March 3, 2027. Between now and then, the two facts that would change the case are whether the FDA's eventual label includes the non-liver-metastases population — the larger half of the modeled colorectal opportunity, which Leerink pegged at roughly $1.3 billion in global peak sales for the whole disease — and whether the follow-on STELLAR-316 trial, testing the drug in earlier-stage colorectal cancer, confirms the franchise's broader promise. Until then, the honest reading is that the company is a strong, well-funded Cabometyx business that is being valued for a growth story the approving agency has not quite finished with.

The number to hold onto is the one most coverage skips: not the 3.5% the stock gave back, but the fact that the entire move forward — approval, launch, revenue, re-rating — now begins no earlier than the third day of March 2027. A three-month extension is a small shift of the calendar. It is a meaningful shift of the moment when the hope you are already paying for is allowed to start becoming earnings.